Paolo Monardo
Overview
Explore the profile of Paolo Monardo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ceresa F, Monardo P, Lacquaniti A, Mammana L, Leonardi A, Patane F
Medicina (Kaunas)
. 2025 Feb;
61(2).
PMID: 40005354
: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) was described in December 2019 for the first time, and it was responsible for a global pandemic. An alarming number of patients...
2.
Casuscelli di Tocco T, Lacquaniti A, Ragno C, Sfravara G, Bocca M, Monardo P
G Ital Nefrol
. 2025 Feb;
41(6).
PMID: 39931967
peritoneal dialysis (PD) is a widely used renal replacement therapy allowing end-stage renal disease patients to undergo a home-based treatment. The remote monitoring (RM) and the telemedicine in patients undergoing...
3.
Chirico V, Lacquaniti A, Tripodi F, Conti G, Marseglia L, Monardo P, et al.
J Clin Med
. 2024 Jun;
13(12).
PMID: 38929977
Acute kidney injury (AKI) is associated with long-term consequences and poor outcomes in the neonatal intensive care unit. Its precocious diagnosis represents one of the hardest challenges in clinical practice...
4.
Surgical Aortic Valve Replacement and Renal Dysfunction: From Acute Kidney Injury to Chronic Disease
Lacquaniti A, Ceresa F, Campo S, Smeriglio A, Trombetta D, Patane F, et al.
J Clin Med
. 2024 May;
13(10).
PMID: 38792474
Surgical aortic valve replacement (SAVR) is often complicated by acute kidney injury (AKI). Identifying patients at risk of AKI is important to start nephroprotective strategies or renal replacement therapy (RRT)....
5.
Lacquaniti A, Smeriglio A, Campo S, La Camera E, Lanteri G, Giunta E, et al.
Biomedicines
. 2024 Mar;
12(3).
PMID: 38540188
Blood purification represents a treatment option for sepsis, improving inflammation and the hyper-activated immune system. This study investigates the binding efficacy of Seraph-100 against 10 CFU/mL of (), (), and...
6.
Lacquaniti A, Ceresa F, Campo S, Patane F, Monardo P
Medicina (Kaunas)
. 2024 Jan;
60(1).
PMID: 38256388
: Several studies revealed a relation between abnormal cardiac remodeling and glomerular filtration rate (GFR) decline, but there are limited data regarding echocardiographic changes in chronic kidney disease (CKD). This...
7.
Chirico V, Tripodi F, Lacquaniti A, Monardo P, Conti G, Ascenti G, et al.
J Clin Med
. 2024 Jan;
13(1).
PMID: 38202251
Contrasting data refer to therapies for vesicoureteral reflux (VUR), such as surgical treatments and continuous antibiotic prophylaxis (CAP). This study evaluated the effectiveness of these approaches in children with VUR,...
8.
Lacquaniti A, Ceresa F, Campo S, Barbera G, Caruso D, Palazzo E, et al.
J Clin Med
. 2023 Aug;
12(16).
PMID: 37629236
Background: Identifying a panel of markers detecting kidney injury before the glomerular filtration rate reduction is a challenge to improving the diagnosis and management of acute kidney injury (AKI) in...
9.
Lacquaniti A, Gargano R, Campo S, Casuscelli di Tocco T, Schifilliti S, Monardo P
Medicina (Kaunas)
. 2023 Jun;
59(6).
PMID: 37374275
Iron deficiency and anemia characterize patients on chronic hemodialysis (HD). Available intravenous iron agents, such as ferric gluconate (FG) and ferric carboxymaltose (FCM), vary in dosing regimens and safety profiles....
10.
Lacquaniti A, Campo S, Russo A, Adamo V, Monardo P
G Ital Nefrol
. 2023 Mar;
40(1).
PMID: 36883921
Tolvaptan (TVP), a vasopressin receptor antagonist, represents a therapeutic option in the syndrome of inappropriate anti-diuresis (SIAD). The aim of this study was to evaluate the effect of TVP to...